Growth Factor Receptor Fusions Predict Therapeutic Sensitivity

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-0458
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Fibroblast Growth Factor Receptor 1 (FGFR1; CD331), FGFR2 and Fibroblast Growth Factor 19 (FGF19) Amplification May Help Predict Sensitivity to FGFR Inhibitors in Cancer

Science-Business eXchange
2012English

Therapeutic Potential of Epidermal Growth Factor Receptor-Related Protein

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Modulation of Receptor Sensitivity: Possible Therapeutic Target?

British Journal of Pharmacology
Pharmacology
2009English

Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma

Clinical Cancer Research
Cancer ResearchOncology
2005English

Pgrmc1 (Progesterone Receptor Membrane Component 1) Associates With Epidermal Growth Factor Receptor and Regulates Erlotinib Sensitivity

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2010English

Fibroblast Growth Factor Receptor 3 Is a Rational Therapeutic Target in Bladder Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Insulin-Like Growth Factor Receptor Signaling in Thyroid Cancers: Clinical Implications and Therapeutic Potential

2012English

Insulin-Like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Fibroblast Growth Factor Receptor (FGFR)

Science-Business eXchange
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy